Plasma-derived therapy technology is advancing on multiple fronts — more efficient fractionation processes extracting higher yields of immunoglobulins and other proteins from each liter of plasma, subcutaneous administration formulations improving patient convenience, and recombinant alternatives replacing plasma-derived products in specific applications. CSL's continuous plasma fractionation technology and Takeda's plasma manufacturing infrastructure represent the most advanced commercial capabilities in the industry. The plasma collection infrastructure — the critical upstream constraint on plasma product supply — is expanding globally, with collection center networks growing to meet increasing demand for immunoglobulins in immunodeficiency and autoimmune indications.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Plasma Fractionation Technology
• Continuous Fractionation
• Subcutaneous Formulation Development
• Recombinant Alternatives
• Plasma Collection Infrastructure
• CSL and Takeda Technology Comparison
• New Plasma-Derived Products
• Competitive Landscape
Table of Contents
1. Executive Summary
2. Technology Landscape Overview
3. Plasma Fractionation Technology
4. Continuous Fractionation
5. Subcutaneous Formulation Development
6. Recombinant Alternatives
7. Plasma Collection Infrastructure
8. CSL and Takeda Technology Comparison
9. New Plasma-Derived Products
10. Competitive Landscape
11. Competitive Landscape
12. Strategic Conclusions and Recommendations
13. Appendix
List of Tables
Table 1. Technology Overview and Key Data 2025
Table 2. Plasma Fractionation Technology
Table 3. Continuous Fractionation
Table 4. Subcutaneous Formulation Development
Table 5. Recombinant Alternatives
Table 6. Plasma Collection Infrastructure
Table 7. CSL and Takeda Technology Comparison
Table 8. New Plasma-Derived Products
Table 9. Competitive Landscape
Table 10. Leading Companies — Technology Investment and Strategy 2025
Table 11. M&A and Partnership Activity 2023-2025
Table 12. Key Risks and Mitigation Strategies
Companies Profiled
Amgen
Gilead Sciences
Regeneron
Biogen
Vertex
BioNTech
Moderna
Genentech
CSL Behring
